In patients with advanced melanoma with tumor PD‐L1 expression of less than 5% who received nivolumab, 114 of the 275 patients relapsed, whereas in patients with tumor PD‐L1 expression of more than 5%, only 31 of the 152 patients relapsed.13 This evidence concerns the gene CD274 and melanoma.